Your browser doesn't support javascript.
loading
Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience.
Miele, Catherine H; Schwab, Kristin; Saggar, Rajeev; Duffy, Erin; Elashoff, David; Tseng, Chi-Hong; Weigt, Sam; Charan, Deepshikha; Abtin, Fereidoun; Johannes, Jimmy; Derhovanessian, Ariss; Conklin, Jeffrey; Ghassemi, Kevin; Khanna, Dinesh; Siddiqui, Osama; Ardehali, Abbas; Hunter, Curtis; Kwon, Murray; Biniwale, Reshma; Lo, Michelle; Volkmann, Elizabeth; Torres Barba, David; Belperio, John A; Sayah, David; Mahrer, Thomas; Furst, Daniel E; Kafaja, Suzanne; Clements, Philip; Shino, Michael; Gregson, Aric; Kubak, Bernard; Lynch, Joseph P; Ross, David; Saggar, Rajan.
Afiliación
  • Miele CH; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Schwab K; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Saggar R; 2 Department of Pulmonary and Critical Care Medicine, Banner University Medical Center, Phoenix, Arizona.
  • Duffy E; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Elashoff D; 3 Department of Medicine Statistics Core.
  • Tseng CH; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Weigt S; 3 Department of Medicine Statistics Core.
  • Charan D; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Abtin F; 3 Department of Medicine Statistics Core.
  • Johannes J; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Derhovanessian A; 4 Department of Pulmonary and Critical Care Medicine.
  • Conklin J; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Ghassemi K; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Khanna D; 6 Department of Radiology.
  • Siddiqui O; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Ardehali A; 4 Department of Pulmonary and Critical Care Medicine.
  • Hunter C; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Kwon M; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Biniwale R; 4 Department of Pulmonary and Critical Care Medicine.
  • Lo M; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Volkmann E; 7 Department of Gastroenterology, and.
  • Torres Barba D; 7 Department of Gastroenterology, and.
  • Belperio JA; 8 Department of Medicine, Scleroderma Program in the Division of Rheumatology, University of Michigan Health System, Ann Arbor, Michigan.
  • Sayah D; 9 Department of Surgery, University of Maryland School of Medicine, Baltimore Maryland; and.
  • Mahrer T; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Furst DE; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Kafaja S; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Clements P; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
  • Shino M; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Gregson A; 10 Department of Rheumatology, University of California Los Angeles Medical Center, Los Angeles, California.
  • Kubak B; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Lynch JP; 1 Department of Internal Medicine, David Geffen School of Medicine at the University of California Los Angeles.
  • Ross D; 4 Department of Pulmonary and Critical Care Medicine.
  • Saggar R; 5 Lung and Heart-Lung Transplant and Pulmonary Hypertension Programs.
Ann Am Thorac Soc ; 13(6): 793-802, 2016 06.
Article en En | MEDLINE | ID: mdl-27078625
RATIONALE: Consideration of lung transplantation in patients with systemic sclerosis (SSc) remains guarded, often due to the concern for esophageal dysfunction and the associated potential for allograft injury and suboptimal post-lung transplantation outcomes. OBJECTIVES: The purpose of this study was to systematically report our single-center experience regarding lung transplantation in the setting of SSc, with a particular focus on esophageal dysfunction. METHODS: We retrospectively reviewed all lung transplants at our center from January 1, 2000 through August 31, 2012 (n = 562), comparing the SSc group (n = 35) to the following lung transplant diagnostic subsets: all non-SSc (n = 527), non-SSc diffuse fibrotic lung disease (n = 264), and a non-SSc matched group (n = 109). We evaluated post-lung transplant outcomes, including survival, primary graft dysfunction, acute rejection, bronchiolitis obliterans syndrome, and microbiology of respiratory isolates. In addition, we defined severe esophageal dysfunction using esophageal manometry and esophageal morphometry criteria on the basis of chest computed tomography images. For patients with SSc referred for lung transplant but subsequently denied (n = 36), we queried the reason(s) for denial with respect to the concern for esophageal dysfunction. MEASUREMENTS AND MAIN RESULTS: The 1-, 3-, and 5-year post-lung transplant survival for SSc was 94, 77, and 70%, respectively, and similar to the other groups. The remaining post-lung transplant outcomes evaluated were also similar between SSc and the other groups. Approximately 60% of the SSc group had severe esophageal dysfunction. Pre-lung transplant chest computed tomography imaging demonstrated significantly abnormal esophageal morphometry for SSc when compared with the matched group. Importantly, esophageal dysfunction was the sole reason for lung transplant denial in a single case. CONCLUSIONS: Relative to other lung transplant indications, our SSc group experienced comparable survival, primary graft dysfunction, acute rejection, bronchiolitis obliterans syndrome, and microbiology of respiratory isolates, despite the high prevalence of severe esophageal dysfunction. Esophageal dysfunction rarely precluded active listing for lung transplantation.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Complicaciones Posoperatorias / Esclerodermia Sistémica / Trasplante de Pulmón / Enfermedades del Esófago Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Ann Am Thorac Soc Año: 2016 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Complicaciones Posoperatorias / Esclerodermia Sistémica / Trasplante de Pulmón / Enfermedades del Esófago Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Ann Am Thorac Soc Año: 2016 Tipo del documento: Article